Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com

Investment analysts at StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a research note issued to investors on Thursday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners began coverage on shares of Lipocine in a report on Tuesday, September 24th. They issued a “buy” rating and a $10.00 target price for the company.

Lipocine Stock Down 1.1 %

LPCN stock opened at $5.23 on Thursday. The company’s 50-day moving average price is $5.03 and its two-hundred day moving average price is $5.17. The firm has a market cap of $27.97 million, a P/E ratio of -6.88 and a beta of 1.23. Lipocine has a 12 month low of $2.82 and a 12 month high of $11.79.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) EPS for the quarter. Equities analysts predict that Lipocine will post -0.78 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Lipocine stock. Renaissance Technologies LLC boosted its holdings in Lipocine Inc. (NASDAQ:LPCN) by 21.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,697 shares of the specialty pharmaceutical company’s stock after buying an additional 4,600 shares during the quarter. Renaissance Technologies LLC owned approximately 0.48% of Lipocine worth $212,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.